criteria were as follows: age > 18 years; Eastern Co-operative Oncology Group (ECOG) performance status (PS) 0-2; bidimensionally measurable disease; normal haematological and biochemical parameters and a glomerular filtration rate greater than 60 ml min -1 . Patients were excluded if they had any significant other medical illness, previous or concomitant malignancy (excluding cervical carcinoma in situ or basal cell carcinoma of skin), cerebral metastases, or had received chemotherapy, radiotherapy or immunotherapy within the previous 4 weeks. Patients who had received prior biochemotherapy, or who were taking longterm corticosteroids, were excluded. Written informed consent was obtained from all patients in accordance with the Royal Marsden Hospital Research and Ethics Committee guidelines.
Prognostic factors identified in earlier studies (Elson et al, 1988; Palmer et al, 1992; Jones et al, 1993; Fossa et al, 1995) were used to categorize patients into three groups. These factors were: PS > 0; more than one metastatic site; interval from diagnosis of primary tumour to treatment of metastatic disease < 2 years. Patients with 0 or 1 factors were defined as good prognosis, patients with 2 factors as moderate prognosis, and patients with 3 factors as poor prognosis.
Pre-treatment evaluation
Pre-treatment assessment included full and differential blood count, electrolytes, calcium, liver enzymes, thyroid function tests and coagulation profile. Baseline electrocardiograms and chest radiographs were also performed. Tumour assessment was by computed tomography (CT) scan and/or plain X-rays as appropriate.
Treatment
A 9-week treatment schedule was employed as in Table 1 . Patients were admitted for treatment during weeks 1 and 4. A Hickman line was inserted during week 4 and warfarin was commenced at a dose of 1 mg daily as prophylaxis against Hickman line-associated thrombosis. Patients who received a second or third cycle of treatment continued their PVI 5FU throughout the entire 9 weeks of these cycles.
Toxicity assessment
Patients were evaluated for toxicity at weeks 1, 4 and 9. Treatment toxicity was assessed using National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) Expanded Common Toxicity Criteria (CTC). Paracetamol and/or naproxen were used to ameliorate the constitutional side-effects of IFN-α and IL-2. Chlorpheniramine was used to relieve pruritus when it occurred and anti-emetics, sedatives and anti-diarrhoeal agents were given as necessary. Intravenous colloids were used for the initial treatment of IL-2-induced hypotension, followed by dopamine if required. Dose modifications for 5FU toxicity were made as follows: mucositis or palmar-plantar erythema (≥ grade 2) or diarrhoea (≥ grade 3), 5FU stopped until resolution of toxicity and restarted with a 25% dose reduction.
Assessment of response
Tumour response was assessed radiologically at week 9 of each cycle. Complete response (CR) was defined as the disappearance of all known disease, partial response (PR) as a 50% or more decrease in the sum of the products of largest and perpendicular diameters of measurable lesions without the appearance of new lesions or progression of any existing lesion, progressive disease (PD) as a 25% or more increase in size of one or more measurable lesions, or the appearance of a new lesion(s) and stable disease (SD) as a < 25% increase or < 50% decrease in the size of measurable lesions without the appearance of new lesions or progression of any existing lesion. Patients who demonstrated CR, PR or SD proceeded to a second cycle of treatment. Patients were subsequently followed up at 3-monthly intervals.
Statistical analysis
Lifetable curves and median survivals were calculated using the Kaplan-Meier method. Fisher's exact test and the Mann-Whitney test for trend were used to compare proportions.
RESULTS

Patient characteristics
The characteristics of the 55 patients who entered the study are shown in Table 2 . Forty-seven patients (85%) had more than one disease site at the time of treatment initiation; 26 patients (47%) had an ECOG PS of 1 and two patients (4%) had a PS of 2. The time from diagnosis to treatment of metastatic disease was < 2 years in 41 patients (74.5%). Table 3 shows the distribution of patients according to prognostic group: 13 patients (23.5%) had a good prognosis, 23 patients (42%) had a moderate prognosis and 19 patients (34.5%) were in the poor prognosis group. Thus, 42 patients (76.5%) were in a moderate or poor prognosis group.
Toxicities
All patients were evaluable for toxicity and Table 4 shows these toxicities according to NCIC-CTG CTC grade (worst toxicity per patient). All patients experienced at least one episode of grade 1 or 2 toxicity. Seventeen patients experienced one or more nonhaematological grade 3 toxicity, and grade 4 toxicity was seen in three patients (one patient grade 4 dyspnoea, one patient grade 4 infection and one patient vomiting and hypotension both grade 4).
Patients were electively admitted to hospital during weeks 1 and 4, as this was the time when higher doses of IL-2 were administered. As a result, toxicities during this period were closely monitored. Twelve patients (22%) failed to complete the first course of treatment because of unacceptable toxicity: six of these were in the poor prognosis group, three in the moderate prognosis group and three in the good prognosis group. Three patients died while on treatment. One patient died of a haemorrhagic cerebrovascular accident during week 9 of her second cycle of treatment. She had been anticoagulated with warfarin following a diagnosis of pulmonary embolism 4 months prior to starting treatment. The second patient died during his third cycle of treatment from previously undiagnosed progressive cerebral metastases associated with oedema which caused tentorial herniation. Post-mortem examination was not undertaken in accordance with the wishes of the next-of-kin. The third patient was admitted to her local hospital with a history of sudden-onset dyspnoea during week 9 of the first cycle of treatment, before any response assessment had been carried out. She died on the day of admission and although no post-mortem was performed, the clinical diagnosis was pulmonary embolism.
Response to treatment and survival
Response to treatment was analysed by intention to treat and the overall response rate was 31% (17 of 55; 95% CI = 19-45%) with a complete response rate of 5.4% (3 of 55; 95% CI = 1.1-15%) and a partial response rate of 25% (14 of 55; 95% CI = 15-39%). Stabilization of disease was seen in a further 13 patients (23.6%). The response rate was 15% in the good prognosis group, 35% in the moderate prognosis group, and 37% in the poor prognosis group. Overall median progression-free survival was 20 weeks (range 1-98+) and median duration of response was 73 weeks (range 6-88+). The median survival by intention to treat was 47 weeks (range 2-134) with no significant differences between prognostic groups. The 1-year survival was 45% overall; interestingly 33% for the good prognosis group and 45% for poor prognosis patients.
An analysis of evaluable patients (Table 5 ) was also undertaken. This excluded patients in whom response could not be assessed, i.e. those who failed to complete one cycle of treatment because of unacceptable toxicity and the patient who died during the first cycle. There were 42 evaluable patients and the response rate in this group was 40% (17 of 42; 95% CI = 26-57%). Their median survival was 79 weeks (range 12-134), 1-year survival 60% and 2-year survival 40%. The median survival of responding patients was 30.9 months (range 4.1-30.9), and the three patients who achieved CR remain progression-free at their last follow up at 14+, 18+ and 23+ months respectively. Their clinical features are shown in Table 6 .
We did not find that response was associated with good prognosis group (Table 5) . On the contrary, there was a trend towards a higher response rate and longer survival in the poor prognosis group, although this did not reach statistical significance.
DISCUSSION
The optimal treatment regimen for patients with metastatic renal cell cancer remains to be established. The highest response rates have been reported for a combination of IFN-α-IL-2-5FU (bolus). The combination of subcutaneous IFN-α-IL-2 with PVI 5FU as reported here utilizes the same doses and schedule of IFN-α and IL-2 as that described by Atzpodien and colleagues for the IFN-α-IL-2-5FU (bolus) combination. We have shown that IFN-α-IL-2-PVI 5FU is feasible and results in high response rates that are comparable with those seen in some other studies of this combination (Atzpodien et al, 1993; 1997; Hofmockel et al, 1996; Ellerhorst et al, 1997) . These encouraging results are of particular interest because of the relatively poor prognostic features of our patients. The reported response rates to IFN-α-IL-2-5FU (bolus) vary widely from 1.8-48.6% (Atzpodien et al, 1993; 1997; Dutcher et al, 1996; Hofmockel et al, 1996; Ellerhorst et al, 1997; Negrier et al, 1997; Ravaud et al, 1998; Tourani et al, 1998) (Table 7) and two main factors probably account for this. First, the patient characteristics of the study populations and secondly, differences in the scheduling of the drugs. For instance, Ravaud and colleagues reported that a combination of interferon, IL-2 and 5FU was inactive with a response rate of only 1.8% . The scheduling and dosing of the agents in this study was very different to the regimen as originally described by Atzpodien and colleagues with IFN-α and IL-2 total doses of 72 MU m -2 and 216 MU m -2 respectively, as opposed to 156 MU m -2 and 150 MU m -2 . Furthermore, in the Ravaud study IL-2 was given subcutaneously for 6 days every other week for 8 weeks, whereas it was given on days 3, 4 and 5 of weeks 1 and 4 and days 1, 3 and 5 of weeks 2 and 3 in the Aztpodien regimen. IFN-α is administered on day 1 of weeks 1 and 4, and days 1, 3 and 5 of weeks 2 and 3 and 5-8 of the Aztpodien regimen, but was given on days 1, 3 and 5 with IL-2 for 8 weeks in the Ravaud trial. Aztpodien gave bolus 5-FU once weekly in weeks 5-8, while Ravaud gave an infusion of 5-FU for 5 days every 4 weeks, starting in week 1. On the other hand, Ellerhorst et al (1997) and Tourani et al (1998) use drug schedules which are quite different again but achieve better response rates than Ravaud. Thus, the scheduling of these drugs (including doses, sequencing, drug combination and modes of administration) is quite different between regimens and may account in some part for the reported differences in activity.
The importance of patient characteristics is demonstrated by several studies that have identified a number of factors which have an impact on the survival of patients with metastatic renal cell cancer following treatment with IFN-α, IL-2 and chemotherapy (Elson et al, 1988; Palmer et al, 1992; Jones et al, 1993; Fossa et al, 1995) . These prognostic factors are ECOG performance status, time from diagnosis to treatment and the number of metastatic sites (Table 3) . Joffe et al (1996) reported lower response rates (17%) to IFN-α-IL-2-5FU (bolus) than Atzpodien and colleagues (48.6%) but the former study included a high proportion of moderate (27%) and poor (56%) prognosis patients. Another example is the recent randomized trial comparing IFN-α-IL-2-5FU (bolus) with single-agent tamoxifen (Atzpodien et al, 1997) , which reported that the median survival of the patients treated in the tamoxifen arm was 14 months. This is considerably better than the median survival reported for IFN-α-treated patients in the randomized MRC trial of IFN-α vs medroxyprogesterone (8.5 months vs 6 months (Medical Research Council Renal Cancer Collaborators, 1999) ). These data suggest that the clinical characteristics of patients in a study may have a profound effect on the results. The high response rate reported here is of particular interest because we have demonstrated that our regimen is active in poor-prognosis patients and three of these patients have obtained durable CRs. Furthermore, the median survival of poorprognosis patients in our series is similar to those with good prognostic features. We have described above how Atzpodien and colleagues mainly treated good-prognosis patients and demonstrated high response rates, while Joffe failed to confirm this activity in a population of poorer-prognosis patients. Our results confirm those of Atzpodien but in a similar patient population to those treated by Joffe and colleagues. A possible explanation for this is our use of PVI 5FU, as opposed to its bolus administration.
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British Journal of Cancer (2000) 83 (8), 980-985 © 2000 Cancer Research Campaign 5FU, an anti-metabolite, is active principally in the S-phase of the cell cycle and therefore may be more effective when given as a protracted venous infusion rather than as a bolus injection, by increasing the proportion of tumour cells in S-phase which are exposed to 5FU. This may be particularly important for tumours with a relatively slow doubling time. In addition, PVI 5FU enables higher dose-intensity of the drug than intravenous bolus administration. PVI 5FU-containing regimens have been associated with high response rates in breast cancer (Smith et al, 1995) and relapsed ovarian cancer (Ahmed et al, 1996) , improved response rates and survival in colorectal cancer (Lokich et al, 1989 ; Metaanalysis Group in Cancer, 1998) and a survival advantage over a standard 5FU-containing regimen in oesophagogastric cancer (Webb et al, 1997) .
The IFN-α-IL-2-PVI 5FU regimen that we describe here is associated with significant toxicity with 36% of patients experiencing grade 3 or 4 toxicity, but most episodes were manageable with appropriate supportive measures. Interestingly, in our study 12 patients (22%) discontinued treatment before completing their first cycle because of unacceptable toxicity. Half of these patients were among the first 15 treated, suggesting that with experience we became better at managing the toxicities associated with this regimen and identifying those individuals who would be more likely to tolerate treatment.
From our results and a review of the other phase II studies combining IFN-α-IL-2-5FU, it is clear that, although there is an element of empiricism in the cytokine schedule, when this is altered response rates appear to fall dramatically (Table 7) . The regimen can be associated with significant toxicity in many patients but the side-effects are manageable in the majority. We would make the following recommendations concerning further studies involving IFN-α-IL-2-5FU: randomization against standard therapy (IFN-α or IL-2 as single agents); inclusion of fit patients with poor prognostic features; the administration of 5FU in a prolonged schedule (PVI 5FU or one of the new oral preparations) should be further explored. In the future, maintenance cytokine schedules need to be developed.
